Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
20 p, 1.4 MB A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART / Gómez, Carmen Elena (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Perdiguero, Beatriz (Centro Nacional de Biotecnología (Madrid, Espanya)) ; García-Arriaza, Juan (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Cepeda, Victoria (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Sánchez-Sorzano, Carlos Óscar (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Jiménez, José Luis (Hospital Gregorio Marañón (Madrid)) ; Muñoz-Fernández, María Ángeles (Hospital Gregorio Marañón (Madrid)) ; Gatell, José María (Hospital Clínic i Provincial de Barcelona) ; López Bernaldo de Quirós, Juan Carlos (Hospital Gregorio Marañón (Madrid)) ; Brander, Christian (Institució Catalana de Recerca i Estudis Avancats (ICREA)) ; García, Felipe (Hospital Clínic i Provincial de Barcelona) ; Esteban, Mariano (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Universitat Autònoma de Barcelona
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. [...]
2015 - 10.1371/journal.pone.0141456
PloS one, Vol. 10 Núm. 11 (november 2015)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.